CTIS2024-512555-21-00进行中（未招募）1 期
A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D1. - PROICM 2018-01 NEX
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histological documentation of adenocarcinoma of the colon or rectum, Patients with metastatic colorectal cancer, Progression during or within 3 months following the last administration of approved standard therapies, which must include a fluoropyrimidine (or raltitrexed), oxaliplatin, irinotecan, anti-VEGF therapy and an anti-EGFR therapy (for RAS wild-type tumors), encorafenib, ECOG performance status =1, Life expectancy of at least 3 months, Patients with A/A CCND1 genotype of rs603965 CCND1, International normalized ratio (INR) = 1.5 x ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) = 1.5 x ULN unless receiving treatment with therapeutic anticoagulation. Patients being treated with anticoagulant, e.g., heparin, will be allowed to participate provided no prior evidence of an underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care
排除标准
- •Patients with A/G or G/G CCND1 genotype of rs603965 CCND1, Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management), Pleural effusion or ascites that causes respiratory compromise (= NCI-CTCAE V5.0 Grade 2 dyspnea), Ongoing infection > Grade 2 NCI-CTCAE V5.0, Known history of human immunodeficiency virus (HIV) infection, Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy, Patients with seizure disorder requiring medication, History of organ allograft, Patients with evidence or history of any bleeding diathesis, irrespective of severity, Any hemorrhage or bleeding event = NCI-CTC V5.0 Grade 3 within 4 weeks prior to the start of study medication, Non-healing wound, ulcer, or bone fracture, Prior treatment with regorafenib or sorafenib, Dehydration NCI-CTCAE V5.0 Grade = 1, Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation, Persistent proteinuria of NCI-CTCAE V5.0 Grade 3 (> 3.5g/24 hours), Patients unable to swallow oral medications, Any malabsorption condition, Chronic inflammatory bowel disease and / or bowel obstruction, Unresolved toxicity higher than NCI-CTCAE V.5.0 Grade 1 attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced neurotoxicity = Grade 2, Concomitant intake of St. John's wort, History of gastrointestinal fistula or perforation, Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to study inclusion, except for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non invasive tumor), Tis (carcinoma in situ) and T1 (lamina propria invasion)]., Prior treatment with TAS 102, Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study drug, Pregnant or breast-feeding subjects. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of study drug, Congestive heart failure = New York Heart Association (NYHA) class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), Myocardial infarction less than 6 months before start of study drug, Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
研究者
相似试验
进行中（未招募）
1 期
A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D1EUCTR2018-002231-24-FRInstitut régional du Cancer de Montpellier312
进行中（未招募）
1 期
_Patients aged =18 years old with metastatic gastro-oesophageal adenocarcinomas after failure of a first-line fluoropyrimidine and platinum-based chemotherapies.EUCTR2018-002374-46-FRICANCER89
进行中（未招募）
不适用
maintenance therapy with regorafenibThe present proposal is aimed to evaluate the efficacy and safety of regorafenib as maintenance therapy in increasing the efficacy of the best available therapy for first line treatment fluoropirimidine based chemotherapy , any variant, in combination with either cetuximab or panitumumab) of RAS wild type metastatic colorectal cancer patients.MedDRA version: 17.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-005428-41-ESDepartment of experimental and clinical medicine F. Magrassi480
进行中（未招募）
不适用
maintenance therapy with regorafenibEUCTR2013-005428-41-DEDepartment of experimental and clincial medicine F. Magrassi480
已完成
不适用
Study of combined neoadjuvant chemotherapy and letrozol in Postmenopausal Women with locally advanced breast cancerBreast cancerACTRN12608000523303Shiraz University of Medical Sciences100